CLOs on the Move

Labviva

www.labviva.com

 
Revolutionizing life sciences procurement. AI-powered digital marketplace for complete transparency into your supply chain Labviva integrates with your existing purchasing software to provide you with actionable insights to make better decisions. Keep your current suppliers, contract pricing, and your purchasing software and processes. Our digital marketplace offers unparalleled visibility into your procurement process, to empower informed decisions to drive science forward without interruptions to your research.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.labviva.com
  • 164 Canal Street
    Boston, MA USA 02114
  • Phone: 800.832.1280

Executives

Name Title Contact Details

Similar Companies

Nashai

Nashai is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BiomedAIliance

BiomedAIliance is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tessera Therapeutics

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Becton Dickinson and Company

Becton Dickinson & Company is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tectonic Therapeutic

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.